“PSMA is a very exciting development in the field of nuclear medicine,” says Hossein Jadvar, MD, PhD.
In this video, Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI, provides an overview of the appropriate use criteria that he helped to develop for prostate-specific membrane antigen PET imaging. Jadvar is a professor of urology and radiology in the Keck School of Medicine at the University of Southern California in Los Angeles.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Commerce Drive
Cranbury, NJ 08512